Updated BEACON: Doublet as Good as Triplet in Metastatic CRC Updated BEACON: Doublet as Good as Triplet in Metastatic CRC

The combination of encorafenib and cetuximab is just as effective as the triplet with binimetinib in improving survival and is now the standard of care, say experts.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news